Total Payments
$396,487
2024 Payments
$47,282
Companies
22
Transactions
324
Medicare Patients
988
Medicare Billing
$166,282
Payment Breakdown by Category
Consulting$151,746 (38.3%)
Other$91,444 (23.1%)
Travel$83,367 (21.0%)
Research$65,002 (16.4%)
Food & Beverage$4,928 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $151,746 | 42 | 38.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $91,444 | 28 | 23.1% |
| Travel and Lodging | $83,367 | 80 | 21.0% |
| Unspecified | $65,002 | 102 | 16.4% |
| Food and Beverage | $4,928 | 72 | 1.2% |
Payments by Type
General
$331,485
222 transactions
Research
$65,002
102 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $186,125 | 123 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $82,762 | 48 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $38,572 | 34 | $0 (2021) |
| F. Hoffmann-La Roche AG | $23,547 | 10 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $14,094 | 27 | $0 (2024) |
| GlaxoSmithKline, LLC. | $13,493 | 20 | $0 (2024) |
| Genentech, Inc. | $12,663 | 16 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $10,617 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $5,419 | 6 | $0 (2018) |
| Novartis Pharma AG | $4,995 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,282 | 42 | SANOFI-AVENTIS U.S. LLC ($24,127) |
| 2023 | $62,670 | 16 | GENZYME CORPORATION ($62,611) |
| 2022 | $67,646 | 38 | GENZYME CORPORATION ($32,918) |
| 2021 | $54,387 | 34 | GENZYME CORPORATION ($28,478) |
| 2020 | $57,755 | 31 | F. Hoffmann-La Roche AG ($19,309) |
| 2019 | $80,121 | 104 | Regeneron Healthcare Solutions, Inc. ($19,535) |
| 2018 | $25,139 | 50 | GENZYME CORPORATION ($12,116) |
| 2017 | $1,487 | 9 | Roche Products Limited ($1,132) |
All Payment Transactions
324 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,750.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids • Category: Immunology | ||||||
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Davol Inc. | ARISTA AH FlexiTip (Device) | Food and Beverage | In-kind items and services | $33.36 | General |
| Category: Surgery | ||||||
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids • Category: Immunology | ||||||
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids • Category: Immunology | ||||||
| 10/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids • Category: Immunology | ||||||
| 10/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $4,250.00 | General |
| Category: Immunology | ||||||
| 10/09/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,664.00 | General |
| 10/08/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 10/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $123.80 | General |
| Category: Respiratory | ||||||
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $866.67 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 09/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 09/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 09/27/2024 | AERIN MEDICAL INC. | VIVAER STYLUS (Device), RHINAER STYLUS | Food and Beverage | In-kind items and services | $132.64 | General |
| Category: EAR NOSE & THROAT | ||||||
| 09/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 09/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | F. Hoffmann-La Roche AG | $20,534 | 8 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $16,750 | 37 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra | SANOFI-AVENTIS U.S. LLC | $7,747 | 21 |
| A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $7,250 | 14 |
| A PhIII RANDOMIZED TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS and PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | F. Hoffmann-La Roche AG | $3,013 | 2 |
| Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (SINUS-52) | SANOFI-AVENTIS U.S. LLC | $2,814 | 5 |
| PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NT 201 IN THE TREATMENT OF LOWER LIMB SPASTICITY CAUSED BY STROKE OR TRAUMATIC BRAIN INJURY IN ADULT SUBJECTS, FOLLOWED BY AN OPEN LABEL EXTENSION WITH OR WITHOUT COMBINED UPPER LIMB TREATMENT | MERZ NORTH AMERICA, INC. | $1,472 | 7 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | SANOFI-AVENTIS U.S. LLC | $1,250 | 1 |
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | GENZYME CORPORATION | $1,250 | 1 |
| A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids | GENZYME CORPORATION | $1,250 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $866.67 | 1 |
| A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | SANOFI-AVENTIS U.S. LLC | $510.00 | 2 |
| A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy w | SANOFI-AVENTIS U.S. LLC | $294.23 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 357 | 486 | $355,824 | $68,679 |
| 2022 | 5 | 207 | 277 | $180,271 | $37,393 |
| 2021 | 4 | 165 | 209 | $94,779 | $23,219 |
| 2020 | 4 | 259 | 362 | $153,691 | $36,991 |
Total Patients
988
Total Services
1,334
Medicare Billing
$166,282
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2023 | 148 | 227 | $195,295 | $38,751 | 19.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $42,680 | $7,962 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 58 | 96 | $37,074 | $7,602 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 61 | $33,386 | $6,724 | 20.1% |
| 31237 | Biopsy or removal of nasal polyp or tissue using an endoscope | Office | 2023 | 13 | 17 | $32,100 | $4,698 | 14.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 30 | 30 | $15,289 | $2,942 | 19.2% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2022 | 81 | 127 | $108,743 | $22,446 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 50 | 72 | $27,250 | $5,916 | 21.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $17,290 | $3,382 | 19.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 30 | 30 | $14,232 | $3,033 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 24 | $12,756 | $2,617 | 20.5% |
| 31231 | Diagnostic examination of nasal passages using an endoscope | Office | 2021 | 75 | 95 | $67,791 | $13,238 | 19.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 70 | $10,656 | $4,751 | 44.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 22 | 28 | $7,448 | $2,933 | 39.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $8,884 | $2,298 | 25.9% |
| 31231 | Diagnostic examination of nasal passages using an endoscope | Office | 2020 | 111 | 167 | $115,731 | $22,040 | 19.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 63 | 81 | $17,840 | $6,911 | 38.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 67 | 96 | $14,024 | $5,682 | 40.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $6,096 | $2,357 | 38.7% |
About Stella Lee
Stella Lee is a Otolaryngology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1851573893.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Stella Lee has received a total of $396,487 in payments from pharmaceutical and medical device companies, with $47,282 received in 2024. These payments were reported across 324 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($151,746).
As a Medicare-enrolled provider, Lee has provided services to 988 Medicare beneficiaries, totaling 1,334 services with total Medicare billing of $166,282. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Otolaryngology
- Location Pittsburgh, PA
- Active Since 12/01/2007
- Last Updated 04/06/2021
- Taxonomy Code 207Y00000X
- Entity Type Individual
- NPI Number 1851573893
Products in Payments
- DUPIXENT (Biological) $254,632
- DUPIXENT (Drug) $37,359
- Xolair (Biological) $37,342
- NO PRODUCT DISCUSSED (Drug) $12,116
- XOLAIR (Biological) $10,414
- NUCALA (Biological) $9,835
- FASENRA (Drug) $9,570
- DUPIXENT DUPILUMAB INJECTION (Biological) $4,935
- FASENRA (Biological) $4,420
- XEOMIN (Biological) $1,472
- PROPEL (Device) $394.11
- ACCLARENT AERA (Device) $204.81
- Xhance (Drug) $134.53
- VIVAER STYLUS (Device) $132.64
- Odactra (Drug) $131.55
- ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM (Device) $130.44
- XPRESS LOPROFILE (Device) $125.86
- RELIEVA SPINPLUS Balloon Sinuplasty System (Device) $99.02
- NSE - CUTTING ACCESSORIES (Device) $63.49
- STRAIGHTSHOT (Device) $55.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Otolaryngology Doctors in Pittsburgh
Umamaheswar Duvvuri, M.d., Ph.d, M.D., PH.D
Otolaryngology — Payments: $48,245
Otolaryngology $48,245
Farrel Buchinsky, Md, MD
Otolaryngology — Payments: $16,245
Otolaryngology $16,245
Dr. Jose Zevallos, Md, MD
Otolaryngology — Payments: $9,963
Otolaryngology $9,963
Dr. Giuseppe Staltari, Md, MD
Otolaryngology — Payments: $7,170
Otolaryngology $7,170
Dr. Eric Wang, Md, MD
Otolaryngology — Payments: $6,726
Otolaryngology $6,726
Dr. Warren Swegal, M.d, M.D
Otolaryngology — Payments: $6,711
Otolaryngology $6,711